Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of genetic analysis company Illumina
So what: A report out of StreetInsider.com spurred the speculation that a larger company in the medical equipment field, like General Electric
Now what: Part of what's driving the chatter is Illumina's beaten-down stock price, which is trading just above 52-week lows. But if the stock price is indicating a truly beaten-up business that is in trouble for the long term, why would someone want to pay a premium to buy the company? On the flip side, if there is indeed a tremendous opportunity for Illumina further out, I don't think the company would be interested in selling at this point. Either way, I'm not buying into the rumors today.
Interested in more info on Illumina? Add it to your watchlist by clicking here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Motley Fool newsletter services have recommended buying shares of Illumina. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is Illumina, Inc. a Buy in 2018?
This gene-sequencing stock soared in 2017. But can its momentum continue in the new year?
What Happened in the Stock Market Today
On a record day for the indexes, Illumina stock rose on a product announcement and positive outlook, and e.l.f. Beauty fell following a lowered growth forecast.
5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce
The gene-sequencing leader had plenty of good news to announce at the major healthcare conference this week.